Biomarkers in the development of anti-angiogenic therapies for ovarian cancer

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 662-672

  Raja, Fharat A ^a   Hook, Jane M ^b   Ledermann, Jonathan A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Angiogenesis; Biomarkers; Ovarian cancer; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CA 125 ANTIGEN; CARBOPLATIN; CD31 ANTIGEN; CEDIRANIB; COMBRETASTATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLATINUM; PROTEIN KINASE B; PROTEIN P27; TAXANE DERIVATIVE; THALIDOMIDE; TREBANANIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; DIGESTIVE SYSTEM PERFORATION; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; HEALTH CARE FINANCING; HUMAN; LOW DRUG DOSE; OVARY CANCER; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS;

EID: 84861661737     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.11.009     Document Type: Review

References (84)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available from [accessed 20.11.11]. http://globocan.iarc.fr.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
3. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
4. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
5. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
6. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
7. Soker S., Takashima S., Miao H.Q., et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
8. Osada R., Horiuchi A., Kikuchi N., et al. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 2006, 37:1414-1425.
9. Boss E.A., Massuger L.F., Thomas C.M., et al. Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001, 91:371-377.
10. Yukita A., Asano M., Okamoto T., et al. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res 2000, 20:155-160.
11. Byrne A.T., Ross L., Holash J., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728.
12. Cooper B.C., Ritchie J.M., Broghammer C.L.W., et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002, 8:3193-3197.
13. Kassim S.K., El-Salahy E.M., Fayed S.T., et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004, 37:363-369.
14. Li L., Wang L., Zhang W., et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004, 24:1973-1979.
15. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
16. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
17. Burger R.A., Sill M.W., Monk B.J., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007, 25:5165-5171.
18. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
19. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J Clin Oncol 2008, 26:76-82.
20. Han E.S., Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol 2007, 105:3-6.
21. Burger R.A., Brady M.F., Bookman M.A., et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010, 28:18s. [suppl; abstr LBA1].
22. Perren T., Swart A.M., Pfisterer J., et al. ICON7: a phase III randomised Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010, 21(Suppl. 8):viii2-viii3.
23. Kristensen G., Perren T., Qian W., et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer 2011, Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, [June 4-8].
24. Ledermann J.A., Marth C., Carey M.S., et al. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer 2011, 21:763-770.
25. Aghajanian C., Finkler N., Rutherford T., et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011, 29:18s. [suppl; abstr LBA5007].
26. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009, 27:5601-5606.
27. Hirte H.W., Vidal L., Fleming G.F., et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008, 26:15s. [suppl; abstr 5521].
28. Friedlander M., Hancock K.C., Rischin D., et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010, 119:32-37.
29. Ledermann J.A., Hackshaw A., Kaye S., et al. A randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 following chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011, 29:3798-3804.
30. Zweifel M., Jayson G.C., Reed N.S., et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011, 22:2036-2041.
31. Karlan B.Y., Oza A.M., Hansen V.L., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol 2001, 28:15s. [suppl; abstr5000].
32. Atkinson A.J., Colburn W., De Gruttola V., et al. Biomarkers and surrogate endpoints; preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
33. Rustin G.J., Vergote I., Eisenhauer E., et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011, 21:419-423.
34. Rustin G.J.S., van der Burg M.E.L., Griffin C.L., et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010, 376:1155-1163.
35. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
36. Azad N.S., Annunziata C.M., Steinberg S.M., et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 2008, 112:1726-1732.
37. Randall-Whitis L., Burger R.A., Sill M., et al. Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (BEV) on a Gynecologic Oncology Group (GOG) phase II trial. J Clin Oncol 2009, 27:15s. [suppl; abstr e16505].
38. Jain R.K., Duda D.G., Willett C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
39. Mandrekar S.J., Sargent D.J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009, 27:4027-4034.
40. Azad N.S., Posadas E.M., Kwitkowski V.E., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26:3709-3714.
41. Nimeiri H., Oza A., Morgan R. Et al.: Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California phase II consortia. Gynecol Oncol 2008, 110:49-55.
42. Schultheis A.M., Lurje G., Rhodes K.E., et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008, 14:7554-7563.
43. Annunziata C.M., Walker A.J., Minasian L., et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010, 16:664-672.
44. Chambers S.K., Clouser M.C., Baker A.F., et al. Overexpression of tumor vascular endothelial growth factor a may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 2010, 16:5320-5328.
45. Han E.S., Burger R.A., Darcy K.M., et al. Predictive and prognostic angiogenic markers in a Gynecologic Oncology Group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010, 119:484-490.
46. Hurteau J.A., Brady M.F., Darcy K.M., et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group study. Gynecol Oncol 2010, 119:444-450.
47. Smerdel M.P., Steffensen K.D., Waldstrøm M., et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010, 118:167-171.
48. Weidner N., Semple J.P., Welch W.R., et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
49. Hollingsworth H.C., Kohn E.C., Steinberg S.M., et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995, 147:33-41.
50. Alvarez A.A., Krigman H.R., Whitaker R.S., et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999, 5:587-591.
51. Stone P.J., Goodheart M.J., Rose S.L., et al. The influence of microvessel density on ovarian carcinogenesis. Gynecol Oncol 2003, 90:566-571.
52. Teoh D.G., Secord A.A. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011, 18:31-43.
53. Thaker P.H., Yazici S., Nilsson M.B., et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 2005, 11:4923-4933.
54. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
55. Chen H., Ye D., Xie X., et al. VEGF, VEGFRs expressions and activated STATS in ovarian epithelial carcinoma. Gynecol Oncol 2004, 94:630-635.
56. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
57. Holtz D.O., Krafty R.T., Mohamed-Hadley A., et al. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med 2008, 6:2.
58. Spannuth W.A., Nick A.M., Jennings N.B., et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009, 124:1045-1053.
59. Ebos J.M.L., Lee C.R., Bogdanovic E., et al. Vascular endothelial growth factor mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008, 68:521-529.
60. Batchelor T.T., Sorensen A.G., di Tomaso E. Et al.: Azd2171, a pan-vegf receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
61. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
62. Bertolini F., Shaked Y., Mancuso P., et al. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6:835-845.
63. Su Y., Zheng L., Wang Q., et al. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J Exp Clin Cancer Res 2010, 1-7.
64. Beaudry P., Force J., Naumov G.N., et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005, 11:3514-3522.
65. Kamat A.A., Kim T.J., Landen C.N., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007, 67:281-288.
66. Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Prac Oncol 2008, 5:194-204.
67. Goode E.L., Maurer M.J., Sellers T.A., et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res 2010, 16:995-1007.
68. Lose F., Nagle C.M., O'Mara T., et al. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol 2010, 119:479-483.
69. Steffensen K.D., Waldstrøm M., Brandslund I., et al. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010, 117:109-116.
70. Smerdel M.P., Waldstrøm M., Brandslund I., et al. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 2009, 19:578-584.
71. O'Connor J.P.B., Jackson A., Parker G.J.M., et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007, 96:189-195.
72. Mitchell C.L., O'Connor J.P., Jackson A., et al. Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol 2010, 21:1982-1989.
73. Leach M.O., Brindle K.M., Evelhoch J.L., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005, 92:1599-1610.
74. Sessa C., Guibal A., Del Conte G., et al. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nat Clin Pract Oncol 2008, 5:378-391.
75. Chen W., Delaloye S., Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007, 25:4714-4721.
76. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11:48-54.
77. Jubb A., Harris A. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010, 11:1172-1183.
78. Dahlberg S.E., Sandler A.B., Brahmer J.R., et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010, 28:949-954.
79. Hurwitz H., Douglas P.S., Middleton J.P., et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 2010, 28:15s. [suppl; abstr 3039].
80. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
81. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
82. Kumaran G.C., Jayson G.C., Clamp A.R. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009, 100:1-7.
83. Vergote I., Trope C.G., Amant F., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363:943-953.
84. Glimelius B., Lahn M. Window of opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol 2011, 22:1717-1725.